Publication

International, multicenter randomized preclinical trials in translational stroke research: it's time to act

Dirnagl, Ulrich
Fisher, Marc
Embargo Expiration Date
Abstract

Translational stroke research is in a crisis, and pharmaceutical companies continue to exit the field. Many reasons for the apparently insurmountable barrier between the bench and bedside in stroke drug development have been identified. It is time to act now to bridge the gap between preclinical and clinical studies of purported new therapies. We strongly believe that it is too early to abandon translational stroke research.

Source

J Cereb Blood Flow Metab. 2012 Jun;32(6):933-5. doi: 10.1038/jcbfm.2012.51. Link to article on publisher's site

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1038/jcbfm.2012.51
PubMed ID
22510602
Other Identifiers
Notes

Republished in: Stroke. 2012 Jun;43(6):1453-4. doi: 10.1161/STROKEAHA.112.653709.

Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
Distribution License